CVC Acquires Therakos Business from Mallinckrodt for $925M

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

CVC Invests KRW 200 Billion in PharmaResearch to Accelerate Global Expansion

September 5, 2024

Pharmaceuticals

Global private equity firm CVC invested KRW 200 billion in South Korea's PharmaResearch via redeemable convertible preferred shares (RCPS). The minority growth investment will support PharmaResearch’s overseas market entry, strategic M&A activity, and R&D/product pipeline expansion in aesthetic injectables and regenerative medicines.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

Carlyle and PAI Partners Acquire Theramex from CVC Capital Partners

March 28, 2022

Pharmaceuticals

Global private equity firms Carlyle and PAI Partners have agreed to acquire Theramex, a London-based specialty pharmaceuticals company focused on women's health, from CVC Capital Partners VI. The new owners plan to accelerate Theramex's international expansion and broaden its women's health product suite to drive further organic and inorganic growth.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

CVC Capital Partners Acquires Majority Stake in Grupo GSH

April 16, 2025

Healthcare Services

CVC Capital Partners (Fund IX) will acquire a majority stake in Grupo GSH from Rede D’Or and Opus Investimentos, subject to regulatory approvals expected in Q3 2025. Grupo GSH, headquartered in Rio de Janeiro, is a leading Brazilian provider of hemotherapy (blood bank) and nuclear medicine/radiopharmacy services that serves hospitals and diagnostic centres across the country; CVC said it will support growth into new product categories and patient services.